Raising the bar: can higher drug spending in the UK deliver for pharma and patients?

Grant Castle noted that that drugs are often recommended for only specific patient subgroups within approved indications, meaning access is restricted to narrower patient populations.

He goes on the further say ‘The proposed increase to the cost-effectiveness threshold appears to be a response to threats of tariffs as high as 100% on imported branded medicines, as well as signs of reduced industry investment, based on what’s been reported in the news. He adds that the MFN policy potentially linking the cost of drugs in the US to that of countries such as the UK, could mean that companies become less willing to adjust their prices to meet the current NICE threshold.